We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Expanded access is no longer available for this treatment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00162227
First Posted: September 13, 2005
Last Update Posted: January 9, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bristol-Myers Squibb
September 9, 2005
September 13, 2005
January 9, 2014
 
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
This study is being conducted to assess the safety and tolerability of an oral liquid solution of Sustiva for antiretroviral therapy-naive or therapy-experienced HIV-1 infected children between the ages 3-16 who are failing or intolerant of current antiretroviral regimen and who are unable to swallow Sustiva capsules.
Not Provided
Expanded Access
Drug: Efavirenz
Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
Other Names:
  • Sustiva
  • BMS-561525
Not Provided
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Puerto Rico,   United States
 
 
NCT00162227
Bristol-Myers Squibb
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
January 2014
To Top